GLP-1 Consumer Research
Published evidence and source-backed reference data on GLP-1 use, costs, access, safety, and the obesity drug pipeline. Each resource identifies its sources, data period, methods, and limitations. Our proposed consumer experience survey remains in planning; no original survey results have been published here.
Self-funded. No affiliate links. No ads.
Topline Findings
82%
of U.S. adults say prescription drug costs are unreasonable
KFF/Peterson, 2024
45M+
GLP-1 prescriptions dispensed in the U.S. in 2023
IQVIA Institute, 2024
27%
of GLP-1 users report experiencing judgment for using weight loss medication
Ro Health Survey, 2024
What the research includes
Published resources
Source compilations, calculations, pricing records, and policy registers
Methods
Documented on each resource; data periods and limitations vary
Consumer survey
Planned; no completed sample or original results published
Survey protocol
Proposed Prolific design; target of at least 500 completed responses
Research
Ozempic Price by Country
9-market dataNine published four-dose 1 mg Ozempic benchmarks standardized across markets, with local price basis, dated ECB conversions, comparability rules, and source conflicts documented.
Ozempic Price History
2017–2027 dataSourced U.S. Ozempic injection list-price history from 2017 through the announced 2027 WAC, with estimated net prices, self-pay, Medicare, Oregon and CPI benchmarks.
Counterfeit Ozempic Lot Numbers
30-record registerA regulator-sourced register of 30 Ozempic identifiers from FDA, WHO, and national alerts, paired with the exact serial, label, device, market, or carton condition that matters.
GLP-1 Prior Authorization Requirements by Insurer
Policy registerVerified 2026 payer policy register comparing BMI floors, comorbidities, lifestyle requirements, initial authorization periods, renewal thresholds, and official source documents.
GLP-1 Insurance Denial Reasons by Insurer
8-policy crosswalkPublished denial triggers across eight exact 2026 insurer and pharmacy-benefit policy instances, with BMI routes, prerequisites, continuation rules, appeal records, and source documents.
Medicare GLP-1 Spending by Prescriber State
CMS dataCMS Medicare Part D gross GLP-1 drug costs by prescriber state in 2024, with a 2023 comparison, product rankings, methodology, limitations, and downloadable data.
GLP-1 Telehealth Funding & M&A Database
17 companies trackedSEC-sourced ledger of funding rounds, acquisitions, public-company revenue, valuations, restructurings, and litigation in GLP-1 telehealth. Confidence-graded, CSV download, updated monthly.
GLP-1 usage statistics and demographics
12 key statisticsSource-labeled GLP-1 use estimates by age, sex, race, insurance, and health, with survey conflicts explained and downloadable ledger, calculations, and charts.
GLP-1 market size and sales ledger
Sales ledgerReported worldwide sales across selected Lilly and Novo products, with an interactive finder, four charts, source notes, and downloadable CSV data.
Obesity drug pipeline tracker: 14 selected late-stage programs
14-program tracker87 Phase 3 records for 14 selected obesity drug programs, with trial status, sources and a free CSV. Updated September 2026.
GLP-1 Telehealth Pricing Records
February 2026 snapshotHistorical records for 15 telehealth providers, with source links, recorded verification dates, change logs, and unresolved data conflicts. These records are not current offers.
How Fast Do Online GLP-1 Sites Prescribe?
49-site studyOriginal study of prescription speed, clinician contact, autocharging, and the hidden steps behind same-day claims.
Secrecy & Stigma
External-data previewPublished external findings on GLP-1 secrecy and stigma. Original consumer survey results are not yet available.
Cost & Financial Impact
External-data previewPublished external findings on cost and financial burden. Original consumer survey results are not yet available.
Cravings & Alcohol
External-data previewPublished external findings on cravings and alcohol. Original consumer survey results are not yet available.
Weight Regain After Stopping GLP-1: Evidence Ledger
Evidence ledgerCompare 20 reports on weight regain, stopping reasons, restart, and maintenance, with 14 key statistics, nine tables, three charts, and the exact downloadable CSV.
Public Opinion & Dating
External-data previewPublished external findings on public opinion and dating. Original consumer survey results are not yet available.
Resources
Planned Survey Methodology
Proposed sample design, quality controls, limitations, and funding disclosures. No original survey results published.
Editorial Policy
How we source, verify, and update research data
Press Kit
Downloadable charts, key findings, and media assets
Changelog
Data updates and revision history
Contact
Press inquiries and data requests
Methodology & Disclosures
Published resources use the sources and methods documented on their own pages. The proposed consumer survey has not been completed. Its current protocol proposes recruiting U.S. adults through Prolific, an opt-in platform; any resulting sample would be nonprobability and would not by itself establish nationally representative estimates or causation. The linked protocol describes plans, not completed fieldwork.
Read the planned survey protocol →Media & Press
For press inquiries, original data requests, or downloadable charts:
hello@weightlossproviderguide.comResponse time: typically <24 hours